These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 29594878)
1. Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation. Osoegawa A; Hashimoto T; Takumi Y; Abe M; Yamada T; Kobayashi R; Miyawaki M; Takeuchi H; Okamoto T; Sugio K Invest New Drugs; 2018 Dec; 36(6):999-1005. PubMed ID: 29594878 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680 [TBL] [Abstract][Full Text] [Related]
3. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. Ninomiya K; Ohashi K; Makimoto G; Tomida S; Higo H; Kayatani H; Ninomiya T; Kubo T; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K Sci Rep; 2018 Jan; 8(1):1955. PubMed ID: 29386539 [TBL] [Abstract][Full Text] [Related]
4. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. Suda K; Mizuuchi H; Murakami I; Uramoto H; Tanaka F; Sato K; Takemoto T; Iwasaki T; Sekido Y; Yatabe Y; Mitsudomi T Lung Cancer; 2014 Aug; 85(2):147-51. PubMed ID: 24939008 [TBL] [Abstract][Full Text] [Related]
5. Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation. Zhao BX; Wang J; Song B; Wei H; Lv WP; Tian LM; Li M; Lv S Mol Med Rep; 2015 Apr; 11(4):2767-74. PubMed ID: 25483995 [TBL] [Abstract][Full Text] [Related]
7. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904 [TBL] [Abstract][Full Text] [Related]
8. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors. Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482 [TBL] [Abstract][Full Text] [Related]
9. HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib. Jin Q; Zheng J; Chen M; Jiang N; Xu X; Huang F Oxid Med Cell Longev; 2021; 2021():6633867. PubMed ID: 33763171 [TBL] [Abstract][Full Text] [Related]
10. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964 [TBL] [Abstract][Full Text] [Related]
11. Osimertinib Did Not Respond to a Pulmonary Adenocarcinoma with Triple Mutations of Epidermal Growth Factor Receptor, G719S, T790M and S768I. Minami S; Ihara S; Tanaka T; Okada H; Hashimoto K; Komuta K Case Rep Oncol; 2019; 12(1):178-182. PubMed ID: 39263343 [TBL] [Abstract][Full Text] [Related]
12. A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells. Li L; Liu C; Wang R; Yang X; Wei X; Chu C; Zhang G; Liu C; Cui W; Xu H; Wang K; An L; Li X Sci Rep; 2024 Oct; 14(1):22895. PubMed ID: 39358400 [TBL] [Abstract][Full Text] [Related]
13. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation. Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595 [TBL] [Abstract][Full Text] [Related]
14. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993 [TBL] [Abstract][Full Text] [Related]
16. Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). Zhong J; Li L; Wang Z; Bai H; Gai F; Duan J; Zhao J; Zhuo M; Wang Y; Wang S; Zang W; Wu M; An T; Rao G; Zhu G; Wang J J Thorac Oncol; 2017 Dec; 12(12):1766-1778. PubMed ID: 28818608 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737 [TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836 [TBL] [Abstract][Full Text] [Related]
19. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor ( Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206 [TBL] [Abstract][Full Text] [Related]
20. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. Kim HR; Cho BC; Shim HS; Lim SM; Kim SK; Chang J; Kim DJ; Kim JH Lung Cancer; 2014 Mar; 83(3):374-82. PubMed ID: 24468202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]